Last reviewed · How we verify
Cofetuzumab Pelidotin (cofetuzumab-pelidotin)
At a glance
| Generic name | cofetuzumab-pelidotin |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer (PHASE1)
- An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cofetuzumab Pelidotin CI brief — competitive landscape report
- Cofetuzumab Pelidotin updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI